Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
FTHthis companyFaeth Therapeutics, Inc.	$11.18	-0.64×	0.72×	0×	-0.3×	-73.2%	0.0%	0.0%	0.0%	-113.4%	-110.9%	-152.2%	0.08×	0.34×	-696.5×	5.06×	0.0%	3	20.19	3	B-
BOLDBoundless Bio, Inc.	$2.45	-0.46×	0.27×	0×	-1.02×	-159.7%	0.0%	0.0%	0.0%	-59.0%	-43.0%	-175.9%	0.5×	-0.55×	0×	8.74×	0.0%	1	-3.14	2	C
JANXJanux Therapeutics, Inc.	$14.14	-7.54×	0.89×	85.51×	-7.39×	-118.0%	79.7%	-1576.7%	-1136.3%	-11.9%	-16.0%	-9.7%	0.02×	0.27×	0×	39.04×	0.0%	3	8.27	2	C+
KURAKura Oncology, Inc.	$7.63	-3.27×	5.23×	13.5×	-2.84×	72.0%	99.9%	-449.9%	-412.9%	-160.0%	-48.8%	-7.8%	0.12×	0.47×	-200.81×	6.06×	0.0%	3	-2.79	2	C
NUVBNuvation Bio Inc.	$4.27	-14.93×	10.01×	48.65×	-15.36×	-33.1%	86.6%	-338.7%	-325.3%	-66.9%	-41.0%	-5.7%	0.03×	0.81×	-15.57×	6.95×	0.0%	3	0.52	1	C-
PBYIPuma Biotechnology, Inc.	$8.12	9.6×	2.28×	1.3×	5.56×	61.0%	74.5%	16.3%	13.6%	23.9%	20.4%	14.0%	0.22×	-0.02×	5.63×	2×	0.0%	7	-1.09	4	A
Peer median	—	-3.27×	2.28×	13.5×	-2.84×	-33.1%	79.7%	-338.7%	-325.3%	-59.0%	-41.0%	-7.8%	0.12×	0.27×	0×	6.95×	0.0%	3	-1.09	2	—